Monovision ideal for most presbyopes

Article

Surgical monovision is an attractive option for presbyopes seeking refractive surgery and wanting freedom from glasses and contact lenses, according to Mark Mannis, MD, University of California, USA.

Surgical monovision is an attractive option for presbyopes seeking refractive surgery and wanting freedom from glasses and contact lenses, according to Mark Mannis, MD, University of California, USA.

Dr Mannis presented results of a study that enrolled 87 subjects, aged 40 years of age or older, undergoing LASIK monovision. Preoperative refractive errors included spherical myopia, myopia with astigmatism, hyperopia, hyperopia with astigmatism and mixed astigmatism. Thirty-five patients had a contact lens trial preoperatively.

Postoperative mean spherical equivalent (SE) was 0.02 D in the distance eye and -1.27 D in the near eye. Overall, 98% of patients were satisfied with the procedure. Two patients underwent monovision reversal; neither had a preoperative contact lens trial. However, 31 eyes underwent LASIK enhancement, which most often was performed for the distance eye.

Dr Mannis commented, "practitioners should expect long chair times preoperatively and a relatively high enhancement rate postoperatively because even small amounts of astigmatism may require correction. In addition to careful screening and counselling, we also recommend a presurgical contact lens trial for all patients, suggest a minimum three-week acclimatization period after surgery, and use of 'glove box' glasses for scoptic conditions. In addition, this method is not recommended for certain patients, including pilots or professional drivers."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.